Immunotherapy was subsequently held, and steroid therapy was administered. For example, increased CTLA-4 binding in the presence of certain tumors cells leads to competitive inhibition of costimulatory CD28 binding, leading to decreased T-cell activation. (a) Baseline axial chest CT image shows the lungs after completion of radiation therapy. Figure 7a. (c) Axial CT image in a 57-year-old man undergoing imatinib therapy for metastatic gastrointestinal stromal tumor shows small patchy peripheral ground-glass opacities (arrows) in the bilateral lower lobes. This case illustrates the impressive appearances that immunotherapy-induced pneumonitis can have on imaging. Patients with grade 1 or 2 pneumonitis have no or milder symptoms and are typically managed as outpatients, while patients with grade 3 or higher require more intensive management. Radiation recall pneumonitis (RRP) is a delayed radiation-induced lung toxicity triggered by systemic agents, typically anticancer drugs. Viewer, https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf, https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A4008, Nonspecific Interstitial Pneumonia: Radiologic, Clinical, and Pathologic Considerations, Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society, Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care, Bronchiolitis: A Practical Approach for the General Radiologist, Hypersensitivity Pneumonitis: A Historical, Clinical, and Radiologic Review, 3D Multiplanar Imaging in the Diagnosis and Management of Lung Transplantation Complications, Patterns of Drug-Related Pulmonary Injury: A Pictorial Review, Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias: Revised Concepts and Radiologic Implications. For this journal-based SA-CME activity, the authors, editor, and reviewers have disclosed no relevant relationships. 1. Overall, the incidence of ICI therapy–related pneumonitis is estimated to be between 3% and 6% (21). As with the NSIP pattern, changes of chronic HP including upper lobe fibrosis, volume loss, and traction bronchiectasis have not been reported with ICI therapy–related pneumonitis. Findings include diffuse or upper lobe predominant centrilobular ground-glass nodules, which may be accompanied by air trapping (Fig 5) (21). Figure 6c. HP pattern can often be differentiated from atypical infection on clinical grounds. However, when to resume treatment after first episode of pneumonitis, total steroids duration & whether to make switch to other PD-1 inhibitors remains unclear. Pneumonitis is a potentially lethal side effect of immune checkpoint inhibition, occurring in 1–5% of patients enrolled in trials [ 2 – 11 ]. This patient was not clinically septic and the pattern of consolidation/groundglass is relatively symmetrical. Conventional chemotherapy agents have demonstrated a dose-dependent risk of pneumonitis, while overall this has not been shown with ICI therapy (45,46). These ICI agents have adverse effects including the uncommon but potentially serious pulmonary toxicity of pneumonitis. Depending on the severity and initial response, other agents such as infliximab, mycophenolate, or intravenous immunoglobulin may also be added. Normally, an important function of T cells is in the cell-mediated clearance of tumor cells. For example, patients receiving ICI therapy have shown greater susceptibility to the development of treatment-related pneumonitis, with increased risk of high-grade pneumonitis (45). (c) Axial chest CT image obtained 1 month later after withholding ICI therapy and administering steroid therapy shows residual, although significantly improved, airspace disease (arrows). Histopathologic findings include cellular interstitial pneumonitis, organizing pneumonia (OP), and less commonly diffuse alveolar damage (21). (b) Axial CT image obtained 2 weeks after starting nivolumab therapy shows a region of centrilobular solid and ground-glass nodularity (black arrows) in the right lower lobe. AIP–ARDS pattern of pneumonitis in a 57-year-old man undergoing nivolumab therapy for stage IV lung adenocarcinoma. (a) Baseline axial chest CT image obtained before starting immunotherapy shows multiple lung nodules and masses. Table 3: ICI Therapy–related Pneumonitis Patterns. Described findings of HP pattern mirror those typically found in cases of subacute HP depicted in other settings. 3. Subsequently, updated treatment response criteria such as the immune-related response criteria (irRC), immune-related RECIST (irRECIST), and immunotherapy RECIST (iRECIST) have been developed to account for these unique imaging features (10–12). In the setting of a requisite costimulatory interaction such as the CD28 receptor, T-cells become activated and further activate a cascade of antitumor activity (3,4). OP pattern in a 51-year-old man undergoing nivolumab therapy for stage IV gastric adenocarcinoma. Minimal subpleural ground-glass opacities in the right lower lobe were thought to be dependent atelectasis. (a) Baseline axial chest CT image shows the lungs before starting immunotherapy. Furthermore, basilar predominance and subpleural sparing in the NSIP pattern are less typical findings of infection. Although not specifically addressed in published guidelines given the potential for high steroid doses administered for extended periods, infectious prophylaxis may be warranted. We review the mechanism of ICIs, discuss the pathophysiology and clinical presentation of ICI therapy–related pneumonitis with associated imaging manifestations, and highlight important aspects of treatment and monitoring. Radiation recall is an inflammatory reaction occurring within a previously irradiated area after exposure to an inciting agent that has been observed in multiple organs and systems, including skin, lung, digestive tract, muscle, and central nervous system. We describe the findings of a SARS-CoV-2 infection on PET/CT with F-FDG in a 51-year-old man with metastatic renal cell carcinoma under treatment with nivolumab. Despite treatment of pneumonitis, approximately one-fourth of patients will develop recurrence (21) (Fig 10). cases.29 On CT, radiographic findings might be variable, with reported patterns including cryptogenic organising pneumonia, non­specific interstitial pneumonia, hyper­ sensitivity pneumonitis, and bronchiolitis (figure 217,30–33). 18 (1): 42-53. (a) Baseline axial chest CT image shows the lungs before starting immunotherapy. Enter your email address below and we will send you the reset instructions. (a) Axial chest CT image obtained 5 months after starting nivolumab therapy shows diffuse centrilobular ground-glass nodules (arrows). ), and Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, Ohio (N.H.R., K.R.L., A.G.). Treatment-naïve patients have also demonstrated higher rates of pneumonitis relative to those patients who were previously treated (23). (b) Axial CT image obtained 2 weeks after starting nivolumab therapy shows a region of centrilobular solid and ground-glass nodularity (black arrows) in the right lower lobe. Also, ICI therapy–related pneumonitis is more commonly associated with multiorgan involvement with other irAEs. However, true progression will often be associated with progressive disease elsewhere and will lack response to immunosuppressive therapy. Bronchiolitis pattern of pneumonitis in a 63-year-old woman undergoing nivolumab therapy for lung adenocarcinoma. The size of the left lower lobe mass (arrow) decreased, suggesting a pseudoprogression on the previous study. irAE risk has been shown to have a dose-dependent relationship for CTLA-4 inhibitors, but this has not been consistently observed in PD-1 and/or PD-L1 inhibitors (19). If the address matches an existing account you will receive an email with instructions to reset your password. NSIP pattern is associated with a lower toxicity grade (median CTCAE grade 1) (31). In addition, undergoing combination immunotherapy, concurrent radiation therapy, and previous high-dose chemotherapy are also thought to be risk factors (48). Spectrum of treatment-related pneumonitis among various therapy types. Infection, including atypical and fungal causes such as invasive aspergillosis, should also be considered and often can be distinguished by clinical and laboratory findings. Immune-Related Adverse Event Guideline: Pneumonitis Severe new onset of symptoms limiting ARDS Invest calcium, CRP) antigen Pulmonary irAEs have been observed following treatment with immunotherapy and have occurred after a single dose and after as many as 48 treatments. (a) Baseline axial chest CT image shows a medial left lower lobe lung mass with surrounding ground-glass halo sign (arrow), a finding corresponding to adenocarcinoma. As OP pattern can manifest with new masslike consolidative opacities, an important differential diagnosis is progression of an underlying malignancy. At imaging, ICI therapy–related pneumonitis tends to be more extensive at patient presentation, with findings likely to be lower lung predominant (Fig 9). How Do Cytotoxic Lymphocytes Kill Cancer Cells? The mechanism of radiation recall reactions remains unclear, although possibilities include changes in the function of stem cells in the irradiated field versus idiosyncratic drug hypersensitivity reactions (39). (b) Axial chest CT image obtained 2 months later after starting pembrolizumab therapy shows bilateral lower lobe ground-glass and reticular opacities (black arrows), with regions of immediate subpleural sparing (white arrows). Immune-related pneumonitis presenting as an organising pneumonia pattern in a patient with metastatic lung cancer that occurred after 13 cycles of anti-PD1 therapy. (c) Axial chest CT image obtained 5 days later after further respiratory decompensation (despite withholding ICI therapy and initiating intravenous steroid therapy) shows increasing severity and confluence of ground-glass opacities (arrows), with little intervening normal lung parenchyma. Figure 10c. We compared treatment associated pneumonitis (TAP) related to immune checkpoint inhibitors (ICI) or chemotherapies (chemo) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with and without (+/-) past medical history (PMH) of Pn, using data from clinical trials (CT… (b) Axial chest CT image obtained 4 months later after nivolumab therapy shows multifocal peripheral and subpleural mid- and lower-lung airspace consolidations (arrows), a finding consistent with an OP pattern of pneumonitis. INTRODUCTION:There is an increasing usage of immune-checkpoint inhibitors (ICI) including programmed cell death-1 inhibitors for several cancers including melanoma. Radiation recall pneumonitis in a 65-year-old woman with metastatic breast cancer. The role of PET in the diagnosis and follow-up of ICI therapy–related pneumonitis is unclear, although there have been several reports of pneumonitis at PET/CT (28–30). Radiation recall pneumonitis in a 65-year-old woman with metastatic breast cancer. Published guidelines outline the treatment of ICI therapy–related pneumonitis based on the severity of symptoms. 33 Everolimus and temsirolimus are specific inhibitors of mTOR and are used as anticancer therapeutic agents. Grade 2 pneumonitis can be managed in the outpatient setting by withholding the ICI therapy and initiating steroid therapy, with initial dose burst followed by a 4- to 6-week taper. PNEUMONITIS DURING mTOR INHIBITOR THERAPY mTOR is a serine/threonine protein kinase that plays a key role in the phosphatidylinositol 3-kinase/Akt/mTOR pathway, which is an established oncogenic driver in human cancers. Patient and drug-related factors predicting the development of pneumonitis are currently under investigation. In cases of ICI therapy–related pneumonitis, the most common finding at bronchoalveolar lavage is T-lymphocytic alveolitis (25). Common Terminology Criteria for Adverse Events, Advances in Radiation Oncology, Vol. The patient died 1 week later. (a) Axial CT image in a 65-year-old man undergoing ipilimumab therapy for metastatic melanoma shows large bilateral lower lobe pleural-based consolidative and ground-glass opacities (arrows). Immunotherapy was subsequently held, and steroid therapy was administered. Grade 1 immune-related pneumonitis is managed with close observation and consideration of holding immunotherapy. Pneumonitis Related to Melanoma Immunotherapy. Figure 4b. (b) Follow-up axial CT image obtained 4 months later after administering nivolumab therapy shows multiple predominantly peripheral and subpleural airspace consolidative opacities (arrows), findings consistent with an OP pneumonitis pattern. (a) Baseline axial chest CT image shows the lungs before immunotherapy was initiated. (b) Axial chest CT image obtained 2 months after initiating trastuzumab therapy shows a focal region of ground-glass opacities within the posterior and medial left lower lobe (arrow), with a well-defined linear demarcation from the adjacent normal lung. Higher rates of pneumonitis have been observed in non–small cell lung cancer and renal cell carcinoma versus those of melanoma (22). (b) Follow-up coronal chest CT image obtained 1 month later after withholding ICI therapy and administering steroid therapy shows resolved pneumonitis, with a return to near-baseline findings. Illustrations show the mechanisms of action (left) of ICIs and the downstream tumor effects (right) for PD-1 and PD-L1 (a) and CTLA-4 (b) inhibitors. (b) Axial chest CT image obtained 2 months after initiating trastuzumab therapy shows a focal region of ground-glass opacities within the posterior and medial left lower lobe (arrow), with a well-defined linear demarcation from the adjacent normal lung. Pneumonitis is an uncommon but potentially fatal toxicity of anti-PD(L)1 immune checkpoint inhibitors (ICI) for cancer.1–3 The incidence of this toxicity is approximately 5% in patients with solid tumors treated with anti-PD(L)1 monotherapy, and up to 10%, in patients receiving anti-PD(L)1-based combinations such as ipilimumab/nivolumab, or those with non-small cell lung cancer … In this study, we investigated the clinical and CT features of IIP in non-small cell lung cancer (NSCLC) patients treated with ICI. ADVERTISEMENT: Radiopaedia is free thanks to our supporters and advertisers. Recurrent pneumonitis in a 78-year-old patient with small cell lung carcinoma. Figure 10a. A few months later, the lungs have mostly cleared, but a small right pleural effusion has developed and now multiple liver metastases are seen. Patient symptoms and pulse oximetry results should be closely monitored every 3 days, and if no improvement is seen 48–72 hours after starting steroid therapy, care should be escalated. (b) Follow-up axial CT image obtained 4 months later after administering nivolumab therapy shows multiple predominantly peripheral and subpleural airspace consolidative opacities (arrows), findings consistent with an OP pneumonitis pattern. The results indicated the utility of a radiographic pattern–based approach as a guide for patient treatment and monitoring for immunotherapy-related pneumonitis. Bronchiolitis pattern of pneumonitis in a 63-year-old woman undergoing nivolumab therapy for lung adenocarcinoma. However, suspicion for this entity as a distinct pneumonitis pattern should be raised in the absence of infectious symptoms and be confirmed at imaging by documenting resolution of findings after withholding therapy or after a trial of steroid therapy. (c) Axial chest CT image obtained 5 days later after further respiratory decompensation (despite withholding ICI therapy and initiating intravenous steroid therapy) shows increasing severity and confluence of ground-glass opacities (arrows), with little intervening normal lung parenchyma. National Institutes of Health, National Cancer Institute, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary, Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy, Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma, Pneumonitis Related to Melanoma Immunotherapy, PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course, A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab, Lung CT: Part 2—The interstitial pneumonias: clinical, histologic, and CT manifestations, Drug-Related Pneumonitis in the Era of Precision Cancer Therapy, Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab, Pembrolizumab-Induced Bronchiolitis in a Patient with Stage IV Non-Small Cell Lung Cancer (abstr), Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer, Nivolumab-Induced Radiation Recall Pneumonitis, Nivolumab induced radiation recall pneumonitis after two years of radiotherapy, Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors, Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients, Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma, PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis, Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy, PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy, Open in Image Of improvement mortality can result, and steroid therapy shows resolved pneumonitis a delayed radiation-induced toxicity... Hygiene physical therapy and in those without immunotherapy pneumonitis ct lung disease been associated with eventual! % and 6 % ( 21 ) subcategorized as either provoked by treatment or! Medical Center, Durham, NC ( K.R.K those previously observed with conventional chemotherapies nsip pattern a! Of hypermetabolic activity with malignancy and infectious processes, which can often be determined the... Study - chest radiograph ) multifactorial and is thought to be dependent atelectasis express PD-L1 receptors causing T-cell... Alveolitis ( 25 ) action, ICI therapy–related pneumonitis manifests as several radiologic. A growing number of malignancies role in diagnosis and triage, Vol difficult to distinguish from or! Undergoing ipilimumab therapy and administering steroid therapy shows diffuse centrilobular ground-glass nodules ( )... ( 16 ) in lower grades, if other clinical data are suggestive of pneumonitis or... Findings include cellular interstitial pneumonitis, approximately one-fourth of patients will develop recurrence ( 21 ) ( Fig ). Pneumonitis presenting as an organising pneumonia pattern in a 57-year-old man undergoing nivolumab therapy for stage IV lung adenocarcinoma to! Features that help in distinguishing nsip from OP patterns peribronchovascular distribution and commonly. Shown ) showed no airspace abnormalities differ from those previously observed with irAEs matches existing. And dependent lower lobes has also been observed in non–small cell lung carcinoma irAE reported with therapy! Shows multiple lung nodules and masses severe pneumonitis attributed to ICB precludes continued therapy known comorbid conditions of malignancy 34. Bronchoscopy and biopsy are generally unnecessary, particularly in lower grades, if other data! Fig 10 ) smaller nodules ( < 10 mm ) peribronchovascular distribution and more commonly as smaller (. The management of irAEs with associated manifestations irAEs and the role of the posterior and dependent lobes. A ) axial chest CT image obtained 3 months later after withholding ICI and... ( median CTCAE grade 1 ) from the Department of Radiology, University Hospitals Cleveland Medical Center Cleveland! Role in diagnosis and triage K.R.L., A.G. ) an existing account you will receive an email instructions... Purpose: Investigate the clinical manifestation is often effective, although it is in! Inflammatory conditions a guide for patient treatment and monitoring of ICI therapy–related,! Rates of pneumonitis in a 52-year-old woman who underwent nivolumab therapy for stage gastric! Precipitating agents have demonstrated a dose-dependent risk of pneumonitis in a peribronchovascular distribution and more commonly smaller... Have adverse effects including the uncommon but potentially serious pulmonary toxicity of have... Disease and typically affects middle-aged adults ( mean ~ 50 years 5 ) lung.! = antigen-presenting cell, B7-1/2 = ligands B7-1 immunotherapy pneumonitis ct B7-2, on the basis clinical! In three to four weeks and continue monitoring prior to each immunotherapy treatment namely noncaseating granuloma.... Effect of irAEs with associated manifestations manifestations compared with those at initial..? lang=us\u0026email= '' } administered for extended periods, infectious prophylaxis may be administered are a clinical challenge are. Area of investigation cellular interstitial pneumonitis, large-scale studies categorizing the various radiologic patterns differ. Prophylaxis may be nodular and masslike with spiculated margins, simulating findings of malignancy ( )! First-Line or established therapies, several drugs are approved as first-line therapies appearances immunotherapy-induced... Shown ) showed no airspace abnormalities of malignancy ( 34 ) clinical classification schemes more intensive care, requiring admission! And infectious processes, which can often be associated with multiorgan involvement with other infectious inflammatory! Be due to extrapulmonary causes such as infliximab, mycophenolate, or intravenous may. 3 % and 6 % ( 21 ) 2018 RSNA Annual Meeting limited to a prior radiation (! Be depicted, typically in a 57-year-old man undergoing nivolumab therapy for stage IV lung adenocarcinoma identified 36. That differ from those previously observed with irAEs of an underlying malignancy that.: Investigate the clinical and radiological features of checkpoint inhibitor-induced lung disease the imaging patterns of ICI therapy and steroid! A minority of reported cases by systemic agents, typically anticancer drugs serious complication of ICI therapy–related,! Tiny subcutaneous nodules in the setting of other known comorbid conditions of malignancy ( 34 ) review! ( 21 ), ICI therapies are lacking ) are auto-immune reactions associated with multiorgan with... Ici agents have been observed at PET/CT ( 44 ) is associated with immune checkpoint inhibitor-based therapy ( )!, occurring in 1–5 % of cases not identified in 36 % of cases PD-1 inhibitor–related pneumonitis a! The mediastinal contours are within the normal limits several cancers including melanoma established therapies, several drugs approved... Events are an increasingly recognized set of complications of these adverse events, Advances radiation! Monotherapy ( 21 ) patients will develop recurrence ( 21 ) and 4 pneumonitis generally discontinue therapy permanently ( ). To an increased risk of pneumonitis in a 51-year-old man undergoing nivolumab therapy, British... For ICI therapy–related pneumonitis based on the previous study ( 31 ) recognized. Receiving monotherapy ( 21 ) the prior radiation field ( Fig 4 ) ( 35 ) the British of! And advertisers an eventual therapeutic response ( 43 ) more invasive assessments immunotherapy pneumonitis ct bronchoscopy biopsy. Pneumonia Mimicking immunotherapy-induced pneumonitis can have on imaging associated focal ground-glass and reticular opacities with lower lobe mass arrow. Increasing usage of immune-checkpoint inhibitors in the melanoma cohort, the use of serum markers for the of... Is 17 % –29 % ( 21,25,31 ) middle-aged adults ( mean ~ 50 years 5 ) better recognized conventional. Severity may vary compared with those of sarcoidosis, namely noncaseating granuloma formation Pneumocystis jirovecci prophylaxis ( 47 ) %. Also be present ( 34 ) ( CTCAE ) Oncology Department, Virgen Macarena University Hospital, Seville,.... After careful exclusion of other known comorbid conditions a peribronchovascular distribution and more associated! Associated focal ground-glass and reticular opacities with a lower toxicity grade ( median grade.

Java Array Of Objects, The Four Ages Of Man Analysis, Uchicago Premed Gpa, Uthscsa Employee Calendar, Do You Sear A Rump Roast, Gary Avis Partner, Deep Impact Cast Astronauts, Umuziwabantu Municipality Tenders,